Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 270-931-7 | CAS number: 68510-93-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 27 Aug - 01 Sep 2014
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- No justification for using different mouse strain than recommended in OECD 442B, individual housing instead of group-housing
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 014
- Report date:
- 2014
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442B (Skin Sensitization: Local Lymph Node Assay: BrdU-ELISA)
- Version / remarks:
- adopted in July 2010
- Deviations:
- yes
- Remarks:
- No justification for using different mouse strain than recommended in OECD 442B, individual housing instead of group-housing
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Landesanstalt für Umwelt, Messungen und Naturschutz Baden-Württemberg, Karlsruhe, Germany
- Type of study:
- mouse local lymph node assay (LLNA)
Test material
- Reference substance name:
- 1-Naphthalenesulfonic acid, 6-diazo-5,6-dihydro-5-oxo-, ester with phenyl(2,3,4-trihydroxyphenyl)methanone
- EC Number:
- 270-931-7
- EC Name:
- 1-Naphthalenesulfonic acid, 6-diazo-5,6-dihydro-5-oxo-, ester with phenyl(2,3,4-trihydroxyphenyl)methanone
- Cas Number:
- 68510-93-0
- Molecular formula:
- all potential esters of C10HH5O3N2SCl and C13H10O4
- IUPAC Name:
- 3-benzoyl-2-hydroxy-6-({[5-oxo-6-(λ⁵-diazynylidene)-5,6-dihydronaphthalen-1-yl]sulfonyl}oxy)phenyl 5-oxo-6-(λ⁵-diazynylidene)-5,6-dihydronaphthalene-1-sulfonate; 4-benzoyl-2,3-bis({[5-oxo-6-(λ⁵-diazynylidene)-5,6-dihydronaphthalen-1-yl]sulfonyl}oxy)phenyl 5-oxo-6-(λ⁵-diazynylidene)-5,6-dihydronaphthalene-1-sulfonate; 4-benzoyl-2,3-dihydroxyphenyl 5-oxo-6-(λ⁵-diazynylidene)-5,6-dihydronaphthalene-1-sulfonate
- Test material form:
- solid
Constituent 1
- Specific details on test material used for the study:
- STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: at room temperature, protected from light
In vivo test system
Test animals
- Species:
- mouse
- Strain:
- other: CBA/CaOlaHsd
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Harlan Winkelmann GmbH, Borchen, Germany
- Females nulliparous and non-pregnant: yes
- Age at study initiation: Pretest and Main test: 8 weeks
- Weight at study initiation: 18.4 - 21.8 g
- Housing: individual
- Diet: VRF1(P) (SDS Special Diets Services, Altrip, Germany), ad libitum
- Water: tap water, ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3
- Humidity (%): 30 - 70
- Air changes (per hr): approx. 10
- Photoperiod (hrs dark / hrs light): 12/12
- IN-LIFE DATES: From: 27 Aug To: 01 Sep 2014
Study design: in vivo (LLNA)
- Vehicle:
- acetone/olive oil (4:1 v/v)
- Remarks:
- (AOO)
- Concentration:
- 10%, 25%, 50%
- No. of animals per dose:
- 5
- Details on study design:
- PRE-SCREEN TESTS:
In the pre-screening test, two concentrations (25 and 50% dissolved in AOO) were selected, and 25 μl of each dose formulation were applied to the ears of each animal (2 mice per concentration), once a day for 3 consecutive days. Animals were observed for clinical signs of systemic toxicity and local irritation at the application site. Furthermore, body weights and ear thickness measurements were performed (before initial application (Day 0) and on Day 5, ear thickness was additionally measured on Day 2). Additionally the ears were punched after sacrifice (Day 5) at the apical area using a biopsy punch and were immediately pooled per animal and weighed using an analytical balance. None of the animals showed any abnormalities or any signs of signifcant irritation (indicated by an erythema score ≥ 3 and /or an increase of more than 25% in ear thickness). No mortality was observed.
Based on these results and considering that 50% was the maximum attainable concentration, 50% (w/v) was selected as the highest test concentration for the main study. This concentration was expected not to induce systemic toxicity, nor to induce an increase in ear thickness exceeding 25% or to induce dermal erythema with a score of 3 or more.
- Compound solubility: 50% (maximum attainable concentration)
- Irritation: no
- Systemic toxicity: no
- Ear thickness measurements: yes, less than 25% increase in ear thickness
- Erythema scores: 0 (each test group, each time point)
MAIN STUDY
ANIMAL ASSIGNMENT AND TREATMENT
- Name of test method: The proliferative capacity of pooled lymph node cells was determined by the incorporation of BrdU measured in a photometer.
- Criteria used to consider a positive response:
BrdU incorporation in test item group at least 1.6-fold higher compared to control group (indicated by the Stimulation Index (SI))
Data compatible with a conventional dose response
Index, calculated for the lymph node weight and -cell count as well as for the ear weight (mean values of treated groups divided by mean values of vehicle control group), higher than 1.55 (for BALB/c mice) for the lymph node cell count and an increase in ear weight exceeding 25% (according to OECD 442B)
TREATMENT PREPARATION AND ADMINISTRATION:
25 µl of the test item (10, 25, 50%), the vehicle alone (AOO) or the positive control (25% hexyl cinnamaldehyde) were applied topically to the entire dorsal surface of each ear of each mouse.The application was repeated on days 2 and 3; local irritation reactions were assessed. On day 5, 500 µl phosphate buffered saline (DPBS) containing 5 mg Bromodeoxyuridine (BrdU) were injected intraperitoneally. 24 hours later, the draining lymph nodes of each ear were excised and pooled per animal. A single cell suspension of lymph node cells was prepared from each mouse by gentle mechanical disaggregation through a 70 μm nylon mesh. The lymph node cells were re-suspended in DPBS. The incorporation of BrdU into lymph node cells was determined using a commercial cell proliferation assay kit (Roche Applied Science, Mannheim, Germany) After fixation and denaturation of the lymph node cells, anti BrdU antibody was added. After removal of the antibody the substrate solution was added. The chromogen formation was determined by the measurement of the absorbance at 370 nm (reference wavelength = 492 nm) (Absorbance-Reader SUNRISE, Tecan). - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Statistics:
- Mann-Whitney-U test for non-parametric comparison of BrdU values, ear weights, lymph node weights and lymph node cell counts
Results and discussion
- Positive control results:
- The positive control substance (25% hexyl cinnamic aldehyde (Batch number: MKBK3783V, SIGMA-ALDRICH, Taufkirchen, Germany) in AOO) induced a positive reaction, determined by a SI of 2.8. Very slight erythema and scaling could be observed. As expected, a statistical and biological relevant increase in lymph node weight and lymph node cell count was observed. Ear weight measurements revealed a statistical but not biological relevant increase.
In vivo (LLNA)
Resultsopen allclose all
- Key result
- Parameter:
- SI
- Remarks:
- mean of 5 values
- Value:
- 0.7
- Test group / Remarks:
- 10 % test group
- Key result
- Parameter:
- SI
- Remarks:
- mean of 5 values
- Value:
- 0.5
- Test group / Remarks:
- 25 % test group
- Key result
- Parameter:
- SI
- Remarks:
- mean of 5 values
- Value:
- 0.7
- Test group / Remarks:
- 50 % test group
- Key result
- Parameter:
- SI
- Remarks:
- mean of 5 values
- Value:
- 2.8
- Test group / Remarks:
- positive control group
- Cellular proliferation data / Observations:
- CELLULAR PROLIFERATION DATA: No significant lymphoproliferation (SI ≥ 1.6) was observed for the test item at treatment concentrations of 10, 25 and 50%.
DETAILS ON STIMULATION INDEX CALCULATION
The SI is derived by dividing the mean BrdU labeling index/mouse of each test item group or positive control group by the mean BrdU labeling index of the vehicle group.
CLINICAL OBSERVATIONS: No mortality or symptoms of systemic toxicity were observed in any treatment group. No signs of irritation (indicated by an erythema score ≥ 3) or any other local effect were observed in any treatment group. No significant increase in lymph node weight, -cell count and ear weight was observed.
BODY WEIGHTS
Body weights changes were within the range commonly recorded for animals of this strain and age.
Any other information on results incl. tables
Table 1: Body weights (Pre-test)
Animal No. |
Concentration % |
Body Weight (g) |
|||
Prior 1st application |
Prior to Sacrifice (Day 5) |
Difference |
Difference % |
||
1 |
25 |
18.5 |
17.6 |
-0.9 |
-4.9 |
2 |
20.2 |
19.2 |
-1 |
-5 |
|
3 |
50 |
20.3 |
19.6 |
-0.7 |
-3.4 |
4 |
19.9 |
19.5 |
-0.4 |
-2 |
|
5 |
AOO |
19.9 |
19.5 |
-0.4 |
-2 |
6 |
20.9 |
20.2 |
-0.7 |
-3.3 |
AOO = Acetone: Olive oil (4:1 (v/v) mixture)
Table 2: Ear thickness (Pre-test)
Animal No. |
Concentration % |
Ear Thickness |
||||||
Prior to 1st Application (mm) |
Prior to 3rd Application (mm) |
Prior to Necropsy (mm) |
Difference |
Ear Swelling |
Difference |
Ear Swelling Day 5 (%) |
||
Mean (Right and Left Ear) |
||||||||
1 |
25 |
0.22 |
0.23 |
0.23 |
0.01 |
4.55 |
0.01 |
4.55 |
2 |
0.23 |
0.23 |
0.23 |
0.01 |
2.22 |
0.01 |
2.22 |
|
3 |
50 |
0.22 |
0.24 |
0.26 |
0.02 |
6.82 |
0.04 |
18.18 |
4 |
0.24 |
0.24 |
0.24 |
0.00 |
0.00 |
0.00 |
0.00 |
|
5 |
AOO |
0.23 |
0.24 |
0.23 |
0.01 |
4.44 |
0.01 |
2.22 |
6 |
0.23 |
0.23 |
0.23 |
0.00 |
0.00 |
0.00 |
0.00 |
Table 3: Ear weights (Pre-test)
Animal No. |
Concentration % |
Ear Weights after Necropsy (mg per animal) |
Mean |
1 |
25 |
27.8 |
27.7 |
2 |
27.5 |
||
3 |
50 |
29.6 |
29.8 |
4 |
30.0 |
||
5 |
AOO |
28.4 |
28.6 |
Table 4: Stimulation index in mice (main test)
Compound |
Concentration [%] |
BrdU labeling Index |
Mean BrdU labeling Index |
Stimulation index (SI) |
Mean SI |
AOO |
100 |
0.17 |
0.11 |
1.50 |
1 |
0.078 |
0.70 |
||||
0.105 |
1.00 |
||||
0.111 |
1.00 |
||||
0.085 |
0.80 |
||||
Test substance |
10 |
0.06 |
0.078 |
0.5 |
0.7 |
0.114 |
1 |
||||
0.086 |
0.8 |
||||
0.076 |
0.7 |
||||
0.053 |
0.5 |
||||
25 |
0.098 |
0.057 |
0.9 |
0.5 |
|
0.051 |
0.5 |
||||
0.058 |
0.5 |
||||
0.05 |
0.5 |
||||
0.029 |
0.3 |
||||
50 |
0.063 |
0.072 |
0.6 |
0.7 |
|
0.061 |
0.6 |
||||
0.092 |
0.8 |
||||
0.069 |
0.6 |
||||
0.072 |
0.7 |
||||
HCA |
25 |
0.316 |
0.310* |
2.90 |
2.8 |
0.309 |
2.8 |
||||
0.369 |
3.4 |
||||
0.231 |
2.1 |
||||
0.323 |
2.9 |
AOO = Acetone: Olive oil (4:1 (v/v) mixture)
HCA = Hexyl cinnamic aldehyde
* statistically significant increase vs. vehicle control group (p<0.05)
Applicant's summary and conclusion
- Interpretation of results:
- other: CLP/ EU GHS criteria not met, no classification required according to Regulation (EC) No 1272/2008
- Conclusions:
- CLP: not classified
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.